Activation barriers to structural transition determine deposition rates of Alzheimer's disease Aβ amyloid

William P. Esler, Arthur M. Felix, Evelyn R. Stimson, Marcel J. Lachenmann, Joseph R. Ghilardi, Yi An Lu, Harry V. Vinters, Patrick W Mantyh, Jonathan P. Lee, John E. Maggio

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Brain amyloid composed of the ≃40-amino-acid human β-amyloid peptide Aβ is integral to Alzheimer's disease pathology. To probe the importance of a conformational transition in Aβ during amyloid growth, we synthesized and examined the solution conformation and amyloid deposition activity of Aβ congeners designed to have similar solution structures but to vary substantially in their barriers to conformational transition. Although all these peptides adopt similar solution conformations, a covalently restricted Aβ congener designed to have a very high barrier to conformational rearrangement was inactive, while a peptide designed to have a reduced barrier to conformational transition displayed an enhanced deposition rate relative to wild-type Aβ. The hyperactive peptide, which is linked to a heritable Aβ amyloidosis characterized by massire amyloid deposition at an early age, displayed a reduced activation barrier to deposition consistent with a larger difference in activation entropy than in activation enthalpy relative to wild-type Aβ. These results suggest that in Alzheimer's disease, as in the prion diseases, a conformational transition in the depositing peptide is essential for the conversion of soluble monomer to insoluble amyloid, and alterations in the activation barrier to this transition affect amyloidogenicity and directly contribute to human disease. (C) 2000 Academic Press.

Original languageEnglish (US)
Pages (from-to)174-183
Number of pages10
JournalJournal of Structural Biology
Volume130
Issue number2-3
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Amyloid
Alzheimer Disease
Peptides
Prion Diseases
Entropy
Amyloidosis
Pathology
Amino Acids
Brain
Growth

Keywords

  • Alzheimer's disease
  • Amyloid
  • Deposition
  • Peptide conformation

ASJC Scopus subject areas

  • Structural Biology

Cite this

Esler, W. P., Felix, A. M., Stimson, E. R., Lachenmann, M. J., Ghilardi, J. R., Lu, Y. A., ... Maggio, J. E. (2000). Activation barriers to structural transition determine deposition rates of Alzheimer's disease Aβ amyloid. Journal of Structural Biology, 130(2-3), 174-183. https://doi.org/10.1006/jsbi.2000.4276

Activation barriers to structural transition determine deposition rates of Alzheimer's disease Aβ amyloid. / Esler, William P.; Felix, Arthur M.; Stimson, Evelyn R.; Lachenmann, Marcel J.; Ghilardi, Joseph R.; Lu, Yi An; Vinters, Harry V.; Mantyh, Patrick W; Lee, Jonathan P.; Maggio, John E.

In: Journal of Structural Biology, Vol. 130, No. 2-3, 2000, p. 174-183.

Research output: Contribution to journalArticle

Esler, WP, Felix, AM, Stimson, ER, Lachenmann, MJ, Ghilardi, JR, Lu, YA, Vinters, HV, Mantyh, PW, Lee, JP & Maggio, JE 2000, 'Activation barriers to structural transition determine deposition rates of Alzheimer's disease Aβ amyloid', Journal of Structural Biology, vol. 130, no. 2-3, pp. 174-183. https://doi.org/10.1006/jsbi.2000.4276
Esler, William P. ; Felix, Arthur M. ; Stimson, Evelyn R. ; Lachenmann, Marcel J. ; Ghilardi, Joseph R. ; Lu, Yi An ; Vinters, Harry V. ; Mantyh, Patrick W ; Lee, Jonathan P. ; Maggio, John E. / Activation barriers to structural transition determine deposition rates of Alzheimer's disease Aβ amyloid. In: Journal of Structural Biology. 2000 ; Vol. 130, No. 2-3. pp. 174-183.
@article{8e8baafd98a848bda3ba136781a20f66,
title = "Activation barriers to structural transition determine deposition rates of Alzheimer's disease Aβ amyloid",
abstract = "Brain amyloid composed of the ≃40-amino-acid human β-amyloid peptide Aβ is integral to Alzheimer's disease pathology. To probe the importance of a conformational transition in Aβ during amyloid growth, we synthesized and examined the solution conformation and amyloid deposition activity of Aβ congeners designed to have similar solution structures but to vary substantially in their barriers to conformational transition. Although all these peptides adopt similar solution conformations, a covalently restricted Aβ congener designed to have a very high barrier to conformational rearrangement was inactive, while a peptide designed to have a reduced barrier to conformational transition displayed an enhanced deposition rate relative to wild-type Aβ. The hyperactive peptide, which is linked to a heritable Aβ amyloidosis characterized by massire amyloid deposition at an early age, displayed a reduced activation barrier to deposition consistent with a larger difference in activation entropy than in activation enthalpy relative to wild-type Aβ. These results suggest that in Alzheimer's disease, as in the prion diseases, a conformational transition in the depositing peptide is essential for the conversion of soluble monomer to insoluble amyloid, and alterations in the activation barrier to this transition affect amyloidogenicity and directly contribute to human disease. (C) 2000 Academic Press.",
keywords = "Aβ, Alzheimer's disease, Amyloid, Deposition, Peptide conformation",
author = "Esler, {William P.} and Felix, {Arthur M.} and Stimson, {Evelyn R.} and Lachenmann, {Marcel J.} and Ghilardi, {Joseph R.} and Lu, {Yi An} and Vinters, {Harry V.} and Mantyh, {Patrick W} and Lee, {Jonathan P.} and Maggio, {John E.}",
year = "2000",
doi = "10.1006/jsbi.2000.4276",
language = "English (US)",
volume = "130",
pages = "174--183",
journal = "Journal of Structural Biology",
issn = "1047-8477",
publisher = "Academic Press Inc.",
number = "2-3",

}

TY - JOUR

T1 - Activation barriers to structural transition determine deposition rates of Alzheimer's disease Aβ amyloid

AU - Esler, William P.

AU - Felix, Arthur M.

AU - Stimson, Evelyn R.

AU - Lachenmann, Marcel J.

AU - Ghilardi, Joseph R.

AU - Lu, Yi An

AU - Vinters, Harry V.

AU - Mantyh, Patrick W

AU - Lee, Jonathan P.

AU - Maggio, John E.

PY - 2000

Y1 - 2000

N2 - Brain amyloid composed of the ≃40-amino-acid human β-amyloid peptide Aβ is integral to Alzheimer's disease pathology. To probe the importance of a conformational transition in Aβ during amyloid growth, we synthesized and examined the solution conformation and amyloid deposition activity of Aβ congeners designed to have similar solution structures but to vary substantially in their barriers to conformational transition. Although all these peptides adopt similar solution conformations, a covalently restricted Aβ congener designed to have a very high barrier to conformational rearrangement was inactive, while a peptide designed to have a reduced barrier to conformational transition displayed an enhanced deposition rate relative to wild-type Aβ. The hyperactive peptide, which is linked to a heritable Aβ amyloidosis characterized by massire amyloid deposition at an early age, displayed a reduced activation barrier to deposition consistent with a larger difference in activation entropy than in activation enthalpy relative to wild-type Aβ. These results suggest that in Alzheimer's disease, as in the prion diseases, a conformational transition in the depositing peptide is essential for the conversion of soluble monomer to insoluble amyloid, and alterations in the activation barrier to this transition affect amyloidogenicity and directly contribute to human disease. (C) 2000 Academic Press.

AB - Brain amyloid composed of the ≃40-amino-acid human β-amyloid peptide Aβ is integral to Alzheimer's disease pathology. To probe the importance of a conformational transition in Aβ during amyloid growth, we synthesized and examined the solution conformation and amyloid deposition activity of Aβ congeners designed to have similar solution structures but to vary substantially in their barriers to conformational transition. Although all these peptides adopt similar solution conformations, a covalently restricted Aβ congener designed to have a very high barrier to conformational rearrangement was inactive, while a peptide designed to have a reduced barrier to conformational transition displayed an enhanced deposition rate relative to wild-type Aβ. The hyperactive peptide, which is linked to a heritable Aβ amyloidosis characterized by massire amyloid deposition at an early age, displayed a reduced activation barrier to deposition consistent with a larger difference in activation entropy than in activation enthalpy relative to wild-type Aβ. These results suggest that in Alzheimer's disease, as in the prion diseases, a conformational transition in the depositing peptide is essential for the conversion of soluble monomer to insoluble amyloid, and alterations in the activation barrier to this transition affect amyloidogenicity and directly contribute to human disease. (C) 2000 Academic Press.

KW - Aβ

KW - Alzheimer's disease

KW - Amyloid

KW - Deposition

KW - Peptide conformation

UR - http://www.scopus.com/inward/record.url?scp=0033863220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033863220&partnerID=8YFLogxK

U2 - 10.1006/jsbi.2000.4276

DO - 10.1006/jsbi.2000.4276

M3 - Article

C2 - 10940224

AN - SCOPUS:0033863220

VL - 130

SP - 174

EP - 183

JO - Journal of Structural Biology

JF - Journal of Structural Biology

SN - 1047-8477

IS - 2-3

ER -